The Semmelweis Reflex: Pandemic Perspectives

May 10, 2021 OMA D11 Doctors' Lounge Event, featuring:

2:39 Steve Kirsch, CEO of the COVID-19 Early Treatment Fund, advocate for fluvoxamine.

19:01 Dr. Pierre Kory, ivermectin advocate, President and Chief Medical Officer of FLCCC.

36:46 Dr. Richard Neel MD, MPH, COL (Retd.) USAF, community physician, advocate for high dose melatonin, recently recognized by the Castroville, Texas COC as “Citizen of the Year” for helping to keep his fellow citizens out of hospitals during the pandemic. He has treated over 2000 COVID patients successfully in the community over the past year.

[source]

FDA Advisory Committee 10/26/2021:

"But, we're never going to learn about how safe this vaccine is unless we start giving it. That's just the way it goes." -Eric Rubin M.D. Editor New England Journal of Medicine

Does this sound like someone who cares about your children's health?

Radicals and cytokines are intimately involved in the genesis of the endothelial damage, which is the common denominator of multi-organ failure in COVID-19. When ARDS occurs, ROS, RNS and cytokine production is out of control, and attempting to contrast all with a single cytokine inhibitor is doomed to fail. Only one drug is capable of inhibiting the production of all three of these classes of substance: methylene blue.

Methylene blue inhibits the formation of superoxide anion (ROS precursor) by blocking the xanthine oxidase pathway; it counteracts the synthesis of nitric oxide (RNS precursor) by direct inhibition of NO-synthase, and inhibits cytokine expression via attenuation of NF-kB signaling.

Methylene blue is a tricyclic phenothiazine, approved by the FDA and EMA for the treatment of methaemoglobinaemia and malaria. It is also used to inactivate viruses in blood products for transfusion, in the presence of UV light. Recent (non peer-reviewed) in vitro studies indicate that it has antiviral activity in the absence of UV light, strengthening the rationale for its use in COVID-19.

However, methylene blue use in patients with glucose-6-phosphate dehydrogenase deficiency is contraindicated due to increased risk of haemolytic anemia. Its concomitant use with serotonin reuptake inhibitors is also contraindicated. Methylene blue is a potent reversible inhibitor of monoamine oxidase A (the enzyme that catalyses serotonin breakdown) and concomitant use with serotonin reuptake inhibitors can inhibit the degradation of serotonin and increase its concentration to toxic levels (serotonin syndrome).